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Commentary
The concept of hormesis has generated   
considerable interest within the biomedical 
and toxicologic communities over the past 
decade (Calabrese 2004, 2005, 2008c, 2009a, 
2009b; Calabrese and Baldwin 2003b; Cook 
and Calabrese 2006a, 2006b; Hoffmann 
2009; Mattson and Calabrese 2008; Scott 
2008). It is within this context that Mushak 
(2009) critiques the growth and development 
of the hormesis concept within the scientific 
community, some of the past publications of 
its proponents, especially those dealing with 
frequency within the toxicologic literature, 
its generality, and the evolving definitional 
concept of hormesis. In this commentary I   
welcome the opportunity to address and rebut, 
where appropriate, these concerns. In general, 
Mushak presents a broad array of comments, 
some of which are technical, whereas others 
are in the realm of speculation and opinion. 
Mushak has raised a number of issues con-
cerning the concept of hormesis, and I address 
these issues point by point below.
The Frequency of the  
Hormetic (U‑Shaped)  
Dose–Response Curve
Much of Mushak’s commentary (Mushak 
2009) focuses on interpretation of results from 
Calabrese and Baldwin (2001), which reported 
on the frequency of hormetic (U-shaped) dose 
responses in the toxicologic literature. In that 
paper, we developed a database of dose–re-
sponse curves obtained from the toxicologic 
literature and used three evalua  tive criteria to 
determine the presence of hormesis: a) statisti-
cal significance—at least one response below 
the no observed adverse effect level (NOAEL) 
that exhibits a statistically significant differ-
ence from the control group; b) data distri-
bution—no 2 × SD/SEM overlap of at least 
one treatment response below the NOAEL 
with control response; and c) alternative 
quantitative—at least three doses below the 
NOAEL with responses ≥ 10% of control 
response. Using studies that met specific entry 
criteria, we (Calabrese and Baldwin 2001) 
reported that 37% (rounded up from 36.6%) 
of the dose responses satisfied one or more of 
these evalua  tive criteria. 
In his critique of our study (Calabrese and 
Baldwin 2001), Mushak dismisses two of the 
three evaluative criteria and reduces the esti-
mate of hormesis frequency from 37% to 11%. 
Mushak justifies this by indicating that only 
the first criterion—statistical significance—is 
an acceptable criterion for evaluating the pres-
ence of hormesis. To arrive at the 11% fre-
quency value, Mushak reduced the number of 
dose responses that met at least one of the three 
evaluative criteria (245) to only dose responses 
that met the criterion for statistical significance 
(74) and divided by the total number of dose 
responses satisfying entry criteria (668). It is 
not appropriate to use only dose responses that 
satisfied the evalua  tive criteria for statistical sig-
nificance in the numerator while retaining all 
possible dose responses for the denominator, as 
was done by Mushak (2009). Dose responses 
that could not meet the evaluation criterion 
for statistical significance (i.e., dose responses 
that did not have hypothesis testing) should 
not be included in the denominator in making 
the final frequency calculation. This point was 
explicitly documented in Table 1 of Calabrese 
and Baldwin (2001). If statistical significance 
was the only evaluative criterion, then there 
were 213 dose responses eligible, and 74 of 
these satisfied the statistical significance evalua-
tion criteria. This is a 34.7% frequency, which 
is consistent with the 36.6% value we reported 
using all evaluative criteria (Calabrese and 
Baldwin 2001).
The argument to exclude the data dis-
tribution criterion from the calculation of 
hormesis frequency is overly restrictive. The 
use of nonoverlapping 95% confidence inter-
vals (CIs) is generally recognized as an alter-
native approach to statistically distinguishing 
two means, similar to the hypothesis-testing 
approach where statistical significance is assessed 
by a p-value < α (used in the CI). In fact, con-
siderable research is available within the statisti-
cal litera  ture comparing hypothesis testing and 
95% CIs. Cumming (2009) stated that 
When 95% CIs on independent means do 
not overlap, the two tailed p-value is less than 
0.05 and there is a statistically significant differ-
ence between the means. However, p for non-
overlapping 95% CI is actually considerably 
smaller than 0.05: If the two CIs just touch, 
p is about 0.01 and the interval can overlap by 
as much as about half the length of one CI arm 
before p becomes as large as 0.05.
This perspective for 95% CIs for SDs has 
been repeatedly affirmed and emphasized 
in the statistical literature (Belia et al. 2005; 
Cumming and Finch 2005; Finch et al. 
2002). These authors also developed a similar 
assessment when SEMs are employed. This 
analysis supports the use of non  overlapping 
CIs as an evaluative criterion for evaluating 
the frequency of hormesis.
With regard to the third evaluative crite-
rion—alternative quantitative—we (Calabrese 
and Baldwin 2001) reported that it was twice 
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as difficult to satisfy this criterion than the other 
two. Specifically, there were 75 dose responses 
meeting the statistical significance and data dis-
tribution criteria that also had three or more 
responses below the NOAEL. This observation 
permitted the opportunity to assess what pro-
portion of these 75 dose responses would have 
also satisfied the alternative quantitative crite-
rion, which provides a means of judging which 
criteria were more stringent. Of the 75 dose 
responses, only 38 (50.6%) would have satisfied 
the alternative quantitative criterion, suggesting 
that this criterion is about twice as rigorous as 
the other two criteria. This interpretation indi-
cates that the alternative quantitative criterion 
is reasonably conservative. Excluding this crite-
rion from the calculation of hormesis frequency 
is not warranted. Our calculations indicate that 
if the dose responses meeting the alternative 
quantitative criterion were normalized with the 
same rigor as the other two, the frequency of 
hormesis would exceed the 37% value reported 
previously (Calabrese and Baldwin 2001). 
Conversely, even if dose responses meeting this 
criterion were excluded and the denominator 
adjusted accordingly, hormesis frequency would 
remain essentially unchanged. 
Experts may not agree with the different 
criteria in the evaluation of dose responses to 
determine frequency of hormesis. Exclusion 
of any of the evaluation criteria, however, 
must be based on sound scien  tific and statis-
tical principles. Most important, it is essen-
tial to use the appropriate denominator in 
any calculation of a frequency of occurrence. 
Not doing so after eliminating an evalua-
tion criterion is an error made by Mushak 
(2009). If one excludes the cases to which 
Mushak objects and calculates a frequency 
using the correct number of possible cases in 
the denominator, the estimate of hormesis 
frequency is very similar to that reported we 
reported (Calabrese and Baldwin 2001).
Mushak (2009) also fails to point out 
additional means by which the methodology 
employed to estimate frequency was conserva-
tive and likely led to further under  estimates of 
the actual hormetic frequency. In another study 
(Calabrese and Baldwin 2003b), we presented 
evidence that responses immediately below 
the estimated threshold (i.e., NOAEL) gave 
evidence of modest toxicity. This is most likely 
because the NOAEL may commonly express a 
limited degree of toxicity even though it does 
not achieve statistical significance. We refer 
to this as “residual” toxicity. The key point is 
that the occurrence of residual toxicity for the 
first response below the NOAEL biases against 
observing possible hormetic responses.
Concerns about the Published 
Record
Mushak (2009) also raises several con-
cerns related to previously published work 
concerning the hormesis hypothesis. For 
example, we (Calabrese and Baldwin 2001) 
made an error in Table 5 in tabu  lating the 
number of dose responses to estimate a false-
positive hormesis response rate. Either an 
addition error or a typing error reversed a “7” 
and a “5” (i.e., 57 versus 75). This error led us 
to calculate a 3.8% positive error rate when it 
should have been 5.2%. This correction does 
not affect the conclusions of the paper.
Mushak also points out that we (Calabrese 
and Baldwin 2001) listed 1,089 data points 
below the NOAEL, whereas 1,791 were listed in 
another paper (Calabrese and Baldwin 2003b). 
Simple methodologic differences account for 
the disparate numbers. We (Calabrese and 
Baldwin 2001) reported 1,089 data points 
based on using two criteria, statistical signifi-
cance and data distribution, which was appro-
priate for the specific analysis in Table 4 of 
that paper for estimation of false positives. In 
another paper (Calabrese and Baldwin 2003a), 
dose responses based on all three evaluation cri-
teria were combined to obtain a larger number. 
This approach was appropriate to the condi-
tions studied in that particular paper.
Mushak (2009) has additional concerns 
about the possibility that some dose–response 
data in support of the hormesis hypothesis may 
have been published more than once because 
of a convergence of publications in certain 
years and therefore possibly double entered 
into the hormesis database (Calabrese and 
Baldwin 2001). We have conducted a detailed 
assessment of all references used in the horme-
sis frequency database and found no evidence 
to support this possibility. Approximately 
95% of articles were from research teams with 
only one publication entry into the database. 
For those research teams with more than one 
publication entry into the database, none had 
duplicate data entries. Double entries cannot 
explain the relatively high frequency of horme-
sis in the database we reported (Calabrese and 
Baldwin 2001).
Finally, Mushak calls for more transparency 
in the presentation of our papers, especially 
Calabrese and Baldwin (2001). This critique 
is puzzling given the detailed description of 
the methods, the description of the entry and 
evaluative criteria, and the presentation and 
interpretation of the results. Furthermore, 
researchers may apply our methodology to any 
data set for comparison.
Validation of the Model
Mushak (2009) argues that the model 
employed in studies on hormesis needs to 
be validated and tested for sensitivity and 
specificity. Our multiple evaluative methods 
were designed to validate the general predic-
tive capacity of the threshold and hormetic 
dose–response models. In the case of our 
2001 study (Calabrese and Baldwin 2001), 
the approach we used was supported with the 
data provided on specificity [e.g., false positive 
(type 1 error)] and sensitivity [e.g., false nega-
tive (type 2 error)]. The hormesis frequency 
estimate was corrected for false-positive and 
false-negative values. These findings indicated 
that the hormesis frequency estimate was not 
particularly susceptible to false-positive error.
Poor Predictability of the 
Threshold Model
In our 2003 study (Calabrese and Baldwin 
2003b) we concluded that hormesis was more 
common than the threshold dose response based 
on the observation that approximately 1,800 
responses below the estimated threshold were 
nonrandomly distributed about the control in a 
manner to strongly support an hormetic inter-
pretation. The ratio of above to below (and 
equal to) control values was 2.5 to 1. Mushak 
(2009), however, argues that “data points were 
not gathered from a purely random sampling 
within the main database . . . .” A careful read-
ing of Calabrese and Baldwin (2003a) would 
find that the nearly 1,800 responses constituted 
the entire database of the dose responses satisfy-
ing the entry criteria. It does not seem logical to 
criticize a sample as non  representative when it 
is the entire database. If, on the other hand, all 
20,285 screened articles were used in determin-
ing the frequency of hormesis, it would intro-
duce substantial negative bias. Clearly, many of 
the sampled studies were not designed to exam-
ine hormesis, and others did not even measure a 
biological response to a chemical agent. A priori 
entry criteria were used to determine the suit-
ability of a data set for inclusion in the analysis 
of hormesis frequency.
Occurrence of False Positives
Mushak (2009) questions whether the occur-
rence of false-positive values in the Calabrese 
and Baldwin (2001) paper were highest with 
the statistical significance criterion, lower 
with the data distribution, and lowest with 
the alternative quantitative criteria (three 
responses ≥ 110% of controls). He concluded 
that the “least problematic and the most 
problematic approaches show the highest and 
lowest false-positive rates, respectively.” We 
(Calabrese and Baldwin 2001) indicated that 
the alternative quantitative approach appears 
to be twice as rigorous as statistical signifi-
cance and data distribution criteria. Thus, it is 
likely that there would be lower false-positive 
rates for methods that are twice as rigorous 
as the statistical significance/data distribu-
tion criteria, and this is what we observed (see 
Table 5 of Calabrese and Baldwin 2001). 
Generality of the Phenomenon
Mushak (2009) also claims that hormesis 
may not be highly generalized. The findings 
shown in Table 3 of Calabrese and Baldwin Hormesis: a conversation with a critic
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(2001), as well as Calabrese and Blain (2005), 
demon  strate that hormetic responses satisfying 
the evaluative criteria are widely distributed 
across biological systems, ranging from plants 
to microbes to invertebrates and vertebrates. 
This observation is extremely commonplace 
in numerous other publications. Furthermore, 
hormetic findings have been reported for 
large numbers of agents and are independent 
of chemical class. The hormetic response is 
also independent of the end point measured. 
These observations indicate that the principle 
of hormesis can be generalized widely. This 
does not mean, however, that the hormetic 
response will occur in all cases. In fact, we have 
identified experimental conditions in which 
hormesis will not be expected, such as with a 
very low background disease incidence. Others 
have reported that there are specific experi-
mental conditions that favor or minimize the 
manifestation of hormetic responses (Vichi 
and Tritton 1992). Such restrictions, how-
ever, do not alter the conclusion that hormesis 
appears to occur over a wide range of biologi-
cal conditions and models. 
In addition, Mushak is also concerned 
about the generality of our findings obtained 
from all the articles published in three journals 
typically publishing papers from environmen-
tal toxicology and pharmacology/biomedical 
sciences. Although it may be of interest to 
extend our work to other journals that focus 
on other or similar end points, our findings 
revealed that there were essentially no major 
differences among the journals with respect 
to the frequency of hormesis, regardless of 
the evaluative criteria employed. These find-
ings were consistent with several thousand 
articles in the peer-reviewed literature showing 
hormesis across model, end point, and chemi-
cal class, making a strong argument that the 
hormesis concept is a very general one.
Questions Concerning 
Statistical Significance
Mushak (2009) raises the issue that the 
hormesis data used in the frequency evalua-
tion (Calabrese and Baldwin 2001) should be 
corrected for multiple tests of statistical analy-
sis on the same data, which could falsely give 
the appearance of significance, as 1 of every 
20 hypothesis tests may be expected to be sig-
nificant at the α = 0.05 level purely due to 
chance. Furthermore, the probability of obtain-
ing a statistically significant result with n tests at 
this level of significance is 1 − 0.95n(1 − prob-
ability of not getting a significant result with 
n tests). The key phrase is “on the same data.” 
Such corrections may be applied when mul-
tiple comparisons are tested in the same experi-
mental system for the same end points and 
have the same likelihood for false-positive find-
ings. In the instance of the hormetic database, 
this is not the case, as the data are obtained 
from highly diverse experimental systems and 
instruments and different biological models, 
and using different end points, study designs, 
and other factors. Standard statistical correc-
tion methods, along with their basic assump-
tions, were not designed to address this issue. 
Of potential relevance may be the area of 
meta-analysis in the field of epidemiology in 
which different study findings are compared 
in an integrative manner. However, even in 
this case there is considerably greater homo-
geneity of end point and method than occurs 
with respect to the hormesis database that is 
not restricted by biological model, end point, 
chemical class, and experimental methods. 
Furthermore, in a major proportion of the 
studies showing hormesis, the findings are 
not the result of a single assay performed only 
once. It is typical for investigators to replicate 
their results via various approaches prior to 
publishing their findings. We typically follow 
the research of individual investigators over 
numerous publications to trace and confirm 
the occurrence and consistency of the hor-
metic response. We also obtain dissertations 
by new investigators as follow-up to their 
journal publications on hormesis to obtain 
more evidence of the consistency of the find-
ings. Investigators commonly are publishing 
data that are highly reproducible and often 
representative of numerous other experiments 
in their laboratories. These studies typically 
lead to deeper mechanistic insight, general-
ized to other biological models, often with 
highly consistent results. Although it is likely 
that there is some proportion of false-positive 
values in the hormesis database used to con-
struct the frequency estimates, discussions 
with biostatisticians and epidemiologists indi-
cate that current correction methods are not 
readily applicable to the hormesis database, 
suggesting the need for further research. The 
suggestion that a correction factor for pos-
sible false-positive findings should be applied 
may be a useful concept, but the critique as it 
relates to the special demands of the hormetic 
database is not appropriate. 
The National Cancer Institute 
Yeast Data Set
In his commentary, Mushak (2009) raises 
concerns about our studies concerning the 
National Cancer Institute (NCI) yeast data set 
(Calabrese et al. 2006a, 2006b, 2008), based 
largely on a letter to the editor by Crump 
(2007). We maintain that information con-
tained in a letter to the editor is not peer 
reviewed and therefore lacks normal standards 
to ensure credibility. More important, Crump 
reanalyzed the data in a manner that was not 
reported by the original investigators and was 
specifically refuted by them (Calabrese et al. 
2006b). His approach also introduced 8-fold 
more variability into the analysis. This extra 
variability resulted in the findings supportive 
of hormesis failing to achieve statistical sig-
nificance. Crump justified his actions because 
the original data of the NCI were lost, and he 
concluded that the way he analyzed the data 
was as likely as what the original investigators 
claimed. I (Calabrese et al. 2007) responded 
to this claim by indicating that we had inter-
viewed the NCI investigators prior to starting 
our work. The NCI research group was clear, 
firm, and consistent in their descriptions of 
their research and statistical methods. After 
Crump’s letter was published, the NCI group 
was reinterviewed and provided unequivo-
cal confirmation verbally and in writing 
of their prior statements. In my opinion, 
Crump (2007) was incorrect in his assump-
tions concerning the reanalysis of the data. 
Furthermore, we surveyed a large number 
of biomedical scientists who perform similar 
assessments as conducted by the NCI team. 
Essentially all performed their statistical analy-
ses as reported by the NCI team. No group or 
individual performed statistical analyses as 
Crump did. A similar survey of biostatisti-
cians at leading research centers indicated that 
no one supported Crump’s approach, whereas 
the methodology of the NCI was consistently 
affirmed. Finally, a survey of the peer-re-
viewed literature of publications with 96-well 
plate assays indicated that none used Crump’s 
method, whereas most used the procedure of 
the NCI. The National Institutes of Health 
also requires that original data be held for 
3 years after the end of the grant. Thus, a sig-
nificant fraction of what we know in science is 
based on published results for which the origi-
nal data may not be available. In sum, it is 
not logical to claim, as Mushak (2009) does, 
that Crump’s method was as plausible as that 
reported by the NCI researchers. Beyond his 
reliance on the discredited analysis of Crump 
(2007), Mushak offers no technical criticisms 
of our yeast frequency studies (Calabrese et al. 
2006a, 2006b, 2008). In fact, the NCI data 
set has consistently revealed high hormetic 
dose–response frequency using multiple types 
of modeling methods, with very differing ana-
lytic strategies. Hormetic findings were com-
mon, robust, and rigorously determined.
Data from the National 
Toxicology Program
Mushak (2009) also raises concerns about the 
frequency of hormesis reported in an analysis 
of data obtained from the National Toxicology 
Program (NTP) (Calabrese and Baldwin 
2003a). We asessed 59 environmentally rele-
vant chemicals in the NTP toxicity database 
for their capacity to exhibit hormesis in dose–
response curves for growth, as evidenced by 
assessment of weight gain. The NTP study 
included bioassays involving both mice and 
rats. We (Calabrese and Baldwin 2003a) Calabrese
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reported that for the 409 dose responses 
reported, there was evidence of hormesis in 
128 (31%) cases. In that study we used a well-
described six-point rating scale to define the 
strength of the hormesis response: no to low, 
low, low to moderate, moderate, moderate to 
high, and high. The 31% value was obtained 
by adding all of the dose responses that showed 
low, low-to-moderate, moderate, moderate-
to-high, and high evidence of hormesis. It is 
true that the large majority of the 128 dose 
responses showing hormesis were classified as 
low evidence (n = 98). The fact that a large 
number of dose responses in the NTP data set 
had a low evidence rating does not detract from 
the fact that a hormesis response was detected 
using the rating scale. Moreover, the data set 
obtained from the NTP included dose-ranging 
studies, usually including five doses and a con-
trol for 2-week and 13-week exposure periods. 
These studies typically use higher doses and 
are not designed to detect effects at doses at 
or below the NOAEL. Nonetheless, hormetic 
responses were still quite common.
In our 2005 paper (Calabrese and Blain 
2005) we specifically compared the rigor of 
the evaluative criteria of the hormesis fre-
quency database (Calabrese and Baldwin 
2001) with that of the larger and more general 
hormesis database. This is relevant to the NTP 
assessment, because the NTP data were evalu-
ated using the criteria of the general hormesis 
database. Even though these databases were 
designed for different purposes and employed 
different evaluative criteria, when all 245 dose 
responses that satisfied the evaluative criteria 
(i.e., hormesis designation) in the hormesis 
frequency database (Calabrese and Baldwin 
2001) were assessed using the scoring system 
employed in the general hormesis database 
(Calabrese and Baldwin 2003a), the distri-
bution of ranked scores was very similar for 
both databases (Table 1). That is, those dose 
responses satisfying evaluative criteria in the 
frequency database showed the same quan-
titative distribution patterns for low, mod-
erate, and high evidence of hormesis as is 
seen in the general hormesis database. These 
findings, therefore, revealed a high level of 
agreement between the two different but com-
plementary evaluative methodologies. This 
strongly suggests that both methodologies had 
a comparable level of evaluative rigor. Thus, 
Mushak’s suggestion that dose responses in 
the low evidence category of the NTP assess-
ment should be excluded (Mushak 2009) is 
not supported by the data.
Language
Mushak (2009) expresses concern about how 
hormesis has been defined and the evolution 
of the conceptual history of hormesis. First, 
because science is dynamic, progressive insights 
will always yield refinements of understand-
ing. This is the nature of scientific inquiry, 
and it is inherently self-correcting. One only 
has to look at the changing conceptualiza-
tion of evolution since it was postulated first 
by Charles Darwin. Second, since the paper 
“Defining Hormesis” (Calabrese and Baldwin 
2002), many biomedical scientists have used 
the hormesis concept to help explain their own 
findings. The growing number of scientists has 
brought forth new levels of biological orga-
nization (i.e., molecular, cellular, organismal, 
and ecologic) in which hormesis is studied, 
leading to new and evolving perspectives. 
Ad hoc Retrospective 
Assessment
Retrospective and integrative assessments of 
published literature can be very important in 
the process of scientific discovery. The retro-
spective assessment approach has not been 
presented as better than a purely experimen-
tal prospective hypothesis testing method but 
complementary to it. In fact, narrow experi-
mental studies would not have addressed the 
specific issue of frequency in as meaningful 
a way. The ad hoc approach has provided a 
valuable foundation to explore the hormesis 
concept within a broader and more integrative 
fashion. It has revealed that the hormesis phe-
nomenon has been reported in multiple fields 
of biology concerned with dose-related phe-
nomena, by many hundreds of independent 
research teams, and has passed numerous and 
independent peer reviews. This supports the 
presence of a general biological principle. That 
it may not be detected under certain circum-
stances should not be surprising.
In addition, the ad hoc perspective has 
been applied to large amounts of data in which 
hormesis was not appreciated by the original 
investigators. It has likewise been applied to 
studies where it was built into the original 
study hypothesis. Retrospective methods such 
as meta-analysis in epidemiology are now 
viewed as mainstream, offering critical insights 
to that discipline. It is also standard in epide-
miologic investigations to use secondary data 
sets for investigation, hypothesis generation, 
and testing. Numerous epidemiologic disserta-
tions are based entirely on the ad hoc use of 
such secondary data sets. Furthermore, many 
outstanding research discoveries were the 
unintended offshoots of serendipitous obser-
vations even though the original experiments 
were not designed to study the phenomenon. 
In fact, every researcher who reflects on their 
data is acting in an ad hoc manner. This is 
called “following their data” rather than the 
idea that led to the data.
The Achievements of Hormesis 
in the Last 15 Years
Mushak (2009) concludes that hormesis has 
generally had little impact over the last 15 years. 
This assertion simply fails to acknowledge the 
gains that hormesis has made within the larger 
scientific community. For example, the num-
ber of citations in the scientific literature on 
hormesis (or hormetic) has rapidly increased. 
In 2008 alone, the Web of Science lists nearly 
2,300 citations. This is up from only 16/year 
throughout the 1980s. This is an indication 
that many researchers are studying and observ-
ing hormesis, using multiple biological systems, 
following a broad range of hypothe  ses, with 
wide and varied funding sources, and that their 
research has passed numerous independent 
peer reviews. All leading (and non  leading) toxi-
cologic textbooks contain sections on hormesis, 
giving it clear standing in the field. Also not 
acknowledged is the fact that the concept of 
hormesis is central to a range of biomedical 
areas such as with anxiolytic drugs (Calabrese 
2008b), anti  seizure drugs (Calabrese 2008d), 
memory drugs (Calabrese 2008a), and others 
(Calabrese 2008c). In fact, all drugs approved 
by the Food and Drug Administration for 
Alzheimer’s disease follow the hormetic dose 
response (Calabrese 2008a). Hormesis is now 
a major influence in aging research (Mattson 
and Calabrese 2008; Rattan 2008) as well 
as in exercise science (Radak et al. 2008) 
and plant biology/weed science (Belz 2008; 
Calabrese and Blain 2009), among others. 
The French Academy of Sciences/National 
Academy of Medicine acknowledged support 
of the hormesis concept in 2005 (Academie 
Nationale de Medecine 2005). A key feature 
is that most research supportive of hormesis 
has been performed totally independently of 
me and my colleagues, including its trans  lation 
from animal studies into the clinic and human 
populations.
Table 1. Comparison of the scores for the dose responses in the hormesis frequency database with the 
general hormesis database.
Frequency databasea Hormesis databaseb
[no. (%)] [no. (%)]
Total  245 (100) 5,632 (100)
Performed hypothesis testing 87 (36) 2,309 (41)
Low 130 (53)  3,185 (57)
Low–moderate 65 (27) 1,040 (19)
Moderate 28 (11) 566 (10)
Moderate–high 12 (5) 250 (4)
High 10 (4)  551 (10)
aData from Calabrese and Baldwin 2001. bData from Calabrese and Blain 2005.Hormesis: a conversation with a critic
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 9 | September 2009  1343
Mushak also states that hormesis has not 
been adopted by public agencies for inclu-
sion in health and regulatory policies proba-
bly because of the singular nature of hormesis 
research and directions followed in hormesis 
methodologies. This interpretation is actually 
incorrect, as noted above for entire areas of 
pharmaceuticals. With respect to health and 
regulatory policies, this comment is highly 
speculative. It is just as likely that horme-
sis has not been included in risk assessment 
methodology and risk characterization by 
regulatory agencies because these agencies are 
highly conservative. A change in policy con-
cerning how to interpret biological activity 
at or near the threshold will require consider-
able consensus between scientists and policy 
specialists and must address multiple political 
issues, cost–benefit analyses, and concerns of 
various advocacy groups and the public. A 
change in policy to accommodate the prin-
ciple of hormesis may also raise issues relative 
to past regulatory actions and records of deci-
sions for environmental cleanups. In any case, 
the perspective that hormesis has had little 
impact over the last 15 years is inaccurate and 
unbalanced, presenting a reader with a distor-
tion of the progress, accomplishments, and 
concept penetration of hormesis within the 
scientific community.
Conclusions
Hormesis has become widely accepted within 
the biomedical and toxicologic communities. 
The concept in now included in leading text-
books in toxicology and continues to be cited 
at a rapidly increasing rate in the scientific lit-
erature. Research supports the generality of 
the principle in numerous plant, microbial, 
invertebrate, and vertebrate models, including 
humans, while being independent of the end 
point measured and chemical class assessed. 
The hormetic dose response has also outper-
formed standard default dose–response mod-
els used by regulatory agencies (i.e., threshold 
and linear at low doses) in direct comparisons 
in making accurate predictions of responses 
below estimated toxicologic and pharmacologic 
thresholds. In his commentary Mushak (2009) 
raises questions about the frequency of horme-
sis, its definition, and how it may be studied. 
Based on his analysis, hormesis has not made 
a substantial contribution to the field and, as 
a concept, is now only less negligible than it 
was 15 years ago. In my opinion, his commen-
tary offers no significant conceptual insights 
concerning hormesis, and its key technical 
criticisms of studies concerning the occurrence 
of hormesis are seriously flawed. Erroneous 
conclusions concerning hormesis are based 
primarily on unsubstantiated dismissal of key 
evaluative criteria to assess the frequency of 
hormesis, miscalculation of the remaining data 
leading to an inappropriate frequency estimate, 
and reliance on scientifically unproven analyti-
cal approaches of key supportive data sets. It is 
unfortunate that Mushak does not recognize 
the broad acceptance and utilization of the 
hormesis concept over the last 15 years.
RefeRences
Academie Nationale de Medecine. 2005. Dose-Effect 
Relationships and Estimation of the Carcinogenic Effects 
of Low Doses of Ionizing Radiation. Available: http://www.
academie-sciences.fr/publications/rapports/pdf/dose_
effet_07_04_05_gb.pdf [accessed 21 July 2009].
Belia S, Fidler F, Williams J, Cumming G. 2005. Researchers 
misunderstand confidence intervals and standard error 
bars. Psychol Methods 10:389–396.
Belz RG. 2008. Stimulation versus inhibition–bioactivity of 
parthenin, a phytochemical from Parthenium hysterophorus 
L. Dose Response 6:80–96.
Calabrese EJ. 2004. Hormesis–basic, generalizable, central to 
toxicology and a method to improve the risk-assessment 
process. Int J Occup Environ Health 10:466–467.
Calabrese EJ. 2005. Historical blunders: how toxicology got 
the dose-response relationship half right. Cell Mol Biol 
51:643–654.
Calabrese EJ. 2008a. Alzheimer’s disease drugs: an application 
of the hormetic dose-response model. Crit Rev Toxicol 
38:419–452.
Calabrese EJ. 2008b. An assessment of anxiolytic drug screen-
ing tests: hormetic dose responses predominate. Crit Rev 
Toxicol 38:489–542.
Calabrese EJ. 2008c. Hormesis and medicine. Br J Clin 
Pharmacol 66:594–617.
Calabrese EJ. 2008d. Modulation of the epileptic seizure 
threshold: implications of biphasic dose responses. Crit 
Rev Toxicol 38:543–556
Calabrese EJ. 2009a. Getting the dose-response wrong: why 
hormesis became marginalized and the threshold model 
accepted. Arch Toxicol 83:227–247.
Calabrese EJ. 2009b. The road to linearity: why linearity at low 
doses became the basis for carcinogen risk assessment. 
Arch Toxicol 83:203–225.
Calabrese EJ, Baldwin LA. 2003b. The hormetic dose response 
model is more common than the threshold model in toxi-
cology. Toxicol Sci 71:246–250.
Calabrese EJ, Baldwin LA. 2003a. Hormesis at the National 
Toxicology Program (NTP): evidence of hormetic dose 
responses in NTP dose-range studies. Nonlinearity Biol 
Toxicol Med 1:455–467.
Calabrese EJ, Baldwin LA. 2001. The frequency of U-shaped 
dose-responses in the toxicological literature. Toxicol Sci 
62:330–338.
Calabrese EJ, Baldwin LA. 2002. Defining hormesis. Hum Exp 
Toxicol 21:91–97.
Calabrese EJ, Blain RB. 2005. The occurrence of hormetic dose 
responses in the toxicological literature, the hormesis data-
base: an overview. Toxicol Appl Pharmacol 202:289–301.
Calabrese EJ, Blain RB. 2009. Hormesis and plant biology. 
Environ Pollut 157:42–48.
Calabrese EJ, Stanek EJ III, Nascarella MA, Hoffmann GR. 
2008. Hormesis predicts low-dose responses better than 
threshold models. Int J Toxicol 7:369–378.
Calabrese EJ, Staudenmayer JW, Stanek EJ. 2006a. Drug 
development and hormesis: changing conceptual under-
standing of the dose response creates new challenges 
and opportunities for more effective drugs. Curr Opin Drug 
Discov Devel 9:117–123.
Calabrese EJ, Staudenmayer JW, Stanek EJ, Hoffmann GR. 
2006b. Hormesis outperforms threshold model in NCI anti-
tumor drug screening data. Toxicol Sci 94:368–378.
Calabrese EJ, Staudenmayer JW, Stanek EJ III, Hoffmann GR. 
2007. Hormesis and high throughput studies: Crump’s analy-
sis lacks credibility [Letter]. Toxicol Sci 98:602–603.
Cook RR, Calabrese EJ. 2006a. Hormesis is biology, not religion 
[Letter]. Environ Health Perspect 114:A688. 
Cook RR, Calabrese EJ. 2006b. The importance of hormesis to 
public health. Environ Health Perspect 114:1631–1635.
Crump KS. 2007. Limitations in the National Cancer Institute 
antitumor drug screening database for evaluating hormesis 
[Letter]. Toxicol Sci 98:599–601. 
Cumming G. 2009. Inference by eye: reading the overlap of inde-
pendent confidence intervals. Stat Med 28:205–220.
Cumming G, Finch S. 2005. Inference by eye. Confidence intervals 
and how to read pictures of data. Am Psychol 60:170–180.
Finch S, Thomason N, Cumming G. 2002. Past and future 
American Psychological Association guidelines for statis-
tical practice. Theory Psychol 12:825.
Hoffmann GR. 2009. A perspective on the scientific, philosophical, 
and policy dimensions of hormesis. Dose Response 7:1–51.
Mattson M, Calabrese EJ. 2008. Best in small doses. New Sci 
199:36–39. 
Mushak P. 2009. Ad hoc and fast forward: the science and con-
trol of hormesis growth and development. Environ Health 
Perspect 117:1333–1338.
Radak Z, Chung HY, Koltai E, Taylor AW, Goto S. 2008. Exercise, 
oxidative stress and hormesis. Ageing Res Rev 7:34–42. 
Rattan SIS. 2008. Hormesis in aging. Ageing Res Rev 7:63–78.
Scott BR. 2008. It’s time for a new low-dose-radiation risk 
assessment paradigm–one that acknowledges hormesis. 
Dose Response 6:333–351.
Vichi P, Tritton TR. 1992. Adriamycin-protection from cell-death 
by removal of extracellular drug. Cancer Res 52:4135–4138.